Drug Approval | October 07, 2025
FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Prolia is a prescription medicine used to treat osteoporosis in women
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
The FDA is beginning rulemaking to close the “adequate provision” loophole
Subscribe To Our Newsletter & Stay Updated
